The CDC's advisory committee unexpectedly tabled a vote on delaying the newborn hepatitis B vaccine, despite pressure from some members questioning its safety. Concerns raised included insufficient evidence on side effects and unclear voting language. While some members cited anecdotal evidence and studies suggesting potential neurodevelopmental risks, the CDC presented data showing the vaccine's overwhelming safety and effectiveness in virtually eliminating neonatal hepatitis B. The committee unanimously approved universal hepatitis B testing for pregnant women. The future of the vaccine recommendation remains uncertain.

Prepared by Olivia Bennett and reviewed by editorial team.